Clinical trial

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

NCT03837977

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-11-13

PhasePHASE2

Study timeline

Study start (actual)2018-11-13Date precision: day

Registry last updated2024-12-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Oncologyunresolved

Neuroendocrine Carcinomaunresolved

Interventions

Liposomal IrinotecanDRUG

FluorouracilDRUG · verified · RxNorm: fluorouracil

Folinic AcidDRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

The Christie NHS Foundation Trustlead sponsor

University of Leedscollaborator

Serviercollaborator

National Institute for Health Research, United Kingdomcollaborator

Mapped research locations

LondonUnited Kingdom1 ManchesterUnited Kingdom1 GlasgowUnited Kingdom1 SheffieldUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03837977 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.